Review
The continuous debate in literature about the usage of iodine-131 dosing for the ablation of thyroid remnants and metastases
Affiliations
- PMID: 19209128
Item in Clipboard
Review
The continuous debate in literature about the usage of iodine-131 dosing for the ablation of thyroid remnants and metastases
Minerva Endocrinol.
2009 Mar.
Abstract
Radioiodine plays an important role in the treatment of thyroid cancer. It is used for thyroid remnant ablation as well as for treatment of metastatic disease. Despite the fact that it is used all over the world for these indications, the exact administered dose is still a subject for
Discussion: Two methods are widely available: the so-called fixed empiric method and the dosimetric one. This review will highlight the aspects of radioiodine in treatment of thyroid cancer and discuss the advantages and disadvantages of the several methods for the calculation of the administered dose.
Similar articles
-
A pragmatic protocol for I-131 rhTSH-stimulated ablation therapy in patients with renal failure.Clin Nucl Med. 2006 Aug;31(8):454-7. doi: 10.1097/01.rlu.0000227013.36421.ce. Clin Nucl Med. 2006. PMID: 16855429
-
Radioiodine therapy for papillary and follicular thyroid carcinoma.Eur J Nucl Med Mol Imaging. 2002 Aug;29 Suppl 2:S479-85. doi: 10.1007/s00259-002-0810-9. Epub 2002 May 9. Eur J Nucl Med Mol Imaging. 2002. PMID: 12192549 Review.
-
[Radioiodine therapy in differentiated thyroid gland carcinoma].Zentralbl Chir. 1997;122(4):266-73. Zentralbl Chir. 1997. PMID: 9221637 Review. German.
-
The evolving role of (131)I for the treatment of differentiated thyroid carcinoma.J Nucl Med. 2005 Jan;46 Suppl 1:28S-37S. J Nucl Med. 2005. PMID: 15653649 Review.
-
[Radioiodine treatment of differentiated thyroid carcinomas: residual ablation].Orv Hetil. 2002 Jun 23;143(25):1557; author reply. Orv Hetil. 2002. PMID: 12577410 Hungarian. No abstract available.
Cited by
-
Radioiodine therapy dosimetry in benign thyroid disease and differentiated thyroid carcinoma.Eur J Nucl Med Mol Imaging. 2010 Apr;37(4):821-8. doi: 10.1007/s00259-010-1398-0. Eur J Nucl Med Mol Imaging. 2010. PMID: 20186542 Review. No abstract available.
-
²¹³Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience.Eur J Nucl Med Mol Imaging. 2014 Nov;41(11):2106-19. doi: 10.1007/s00259-014-2857-9. Epub 2014 Jul 29. Eur J Nucl Med Mol Imaging. 2014. PMID: 25070685 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
